Key result
Autologous hematopoietic stem cell transplant for cardiac amyloidosis and LCDD yielded a median overall survival of 4.48 years versus 1.82 years with chemotherapy alone (p=0.69).
Why the study?
Cardiac amyloidosis and light chain deposition disease are the most common cause of death in AL amyloidosis or light chain deposition disease.
Does autologous hematopoietic stem cell transplant improve overall survival compared to chemotherapy alone in patients with cardiac amyloidosis or LCDD?
Population
50 patients with cardiac amyloidosis or LCDD
Comparison
Autologous hematopoietic stem cell transplant vs chemotherapy only
Design
Single-institution retrospective database study
Authors
Loading...
ASCT should not yet change practice over chemotherapy; leaves open survival benefit in cardiac amyloidosis or LCDD.
Observational (n=50)
No
Does autologous hematopoietic stem cell transplant improve overall survival compared to chemotherapy alone in patients with cardiac amyloidosis or LCDD?
Absolute Event Rate: 4.48% vs 1.82%
p-value: p=0.69
Autologous stem cell transplant is feasible for cardiac amyloidosis and LCDD, though the numerical increase in median overall survival compared to chemotherapy alone was not statistically significant in this cohort.
Abdallah et al. (2019) conducted an observational in Cardiac AL-amyloidosis and cardiac light chain deposition disease (n=50). Autologous hematopoietic stem cell transplant (ASCT) vs. Bortezomib-based chemotherapy alone was evaluated on Overall survival (p=0.69). Autologous hematopoietic stem cell transplant for cardiac amyloidosis and LCDD yielded a median overall survival of 4.48 years versus 1.82 years with chemotherapy alone (p=0.69).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: